Published in Br J Cancer on August 01, 1996
Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer (2004) 1.37
Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization. Neoplasia (2000) 1.10
Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surg Today (2011) 0.95
Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol (2014) 0.91
Identification of genetic changes associated with drug resistance by reverse in situ hybridization. Br J Cancer (1997) 0.85
Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol (2016) 0.83
Topoisomerase I as a biomarker: detection of activity at the single molecule level. Sensors (Basel) (2014) 0.82
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer (2016) 0.79
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. J Exp Clin Cancer Res (2016) 0.75
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. BMC Cancer (2017) 0.75
High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones. Science (1990) 10.72
Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci U S A (1994) 5.74
Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res (1989) 2.71
Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res (1994) 1.93
The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst (1993) 1.84
Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene (1991) 1.81
Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst (1994) 1.79
Isochromosomes in neoplasia. Genes Chromosomes Cancer (1994) 1.64
Camptothecins: from bench research to hospital wards. Cancer Res (1994) 1.57
DNA topoisomerase I is essential in Drosophila melanogaster. Proc Natl Acad Sci U S A (1993) 1.44
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res (1994) 1.38
Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest (1994) 1.34
Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer (1993) 1.20
Localization of the active type I DNA topoisomerase gene on human chromosome 20q11.2-13.1, and two pseudogenes on chromosomes 1q23-24 and 22q11.2-13.1. Hum Genet (1989) 1.17
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res (1991) 1.16
Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer (1995) 1.16
Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc Natl Acad Sci U S A (1988) 1.11
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer (1994) 0.97
Semiautomated DNA probe mapping using digital imaging microscopy: II. System performance. Cytometry (1995) 0.95
Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer (1993) 0.93
Structure of the human type I DNA topoisomerase gene. J Biol Chem (1991) 0.92
Semiautomated DNA probe mapping using digital imaging microscopy: I. System development. Cytometry (1995) 0.86
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene (1999) 2.00
Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer (1999) 1.40
Targeting telomerase for cancer therapeutics. Br J Cancer (2008) 1.35
Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene (1997) 1.33
Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie (2007) 1.26
Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer (1995) 1.16
Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. Oncogene (1998) 1.16
A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene (2009) 1.14
Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene (2006) 1.14
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer (1996) 1.12
Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization. Neoplasia (2000) 1.10
Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst (1995) 1.05
Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3. Neoplasia (2001) 1.05
Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer (1996) 1.00
High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer (2008) 0.98
Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene (2001) 0.98
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer (1994) 0.97
Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. Cancer Res (2001) 0.94
Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer (1993) 0.93
Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res (1996) 0.91
Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis (1999) 0.87
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol (2005) 0.87
Telomerase in (pre)neoplastic cervical disease. Hum Pathol (2000) 0.86
A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging. Biochim Biophys Acta (2009) 0.86
Identification of genetic changes associated with drug resistance by reverse in situ hybridization. Br J Cancer (1997) 0.85
Amplification of fluorescent in situ hybridisation signals in formalin fixed paraffin wax embedded sections of colon tumour using biotinylated tyramide. Mol Pathol (1997) 0.84
Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization. Oncogene (1998) 0.83
Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res (1994) 0.82
Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate. Prostate Cancer Prostatic Dis (2004) 0.82
Chromosomal and genetic alterations of 7,12-dimethylbenz[a]anthracene-induced melanoma from TP-ras transgenic mice. Mol Carcinog (1997) 0.81
Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia (2005) 0.81
Mapping of the gene for the mouse telomerase RNA component, Terc, to chromosome 3 by fluorescence in situ hybridization and mouse chromosome painting. Genomics (1997) 0.81
Expression of telomerase RNA in oesophageal and oral cancer. J Oral Pathol Med (2001) 0.81
Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill. Oncogene (2001) 0.81
Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage. Br J Cancer (1999) 0.79
Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer. Ann Oncol (1994) 0.79
The genetic basis of human keratinocyte immortalisation in squamous cell carcinoma development: the role of telomerase reactivation. Eur J Cancer (1997) 0.77
Intra-peritoneal administration of genetic therapies: promises and pitfalls. Minerva Ginecol (2004) 0.76
Progeroid syndromes: models for stem cell aging? Biogerontology (2011) 0.75